ADALIMUMAB
adalimumab 20 mg/0.4 mL injection, 0.4 mL syringe
ADALIMUMAB (14975E)
14975E
Manner of administration:Injection
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 1 treatment (Whole body) - biological medicine-naive patient
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 2 treatment (Whole body) - Change of treatment, or, recommencement of treatment
after a break in biological medicine of less than 5 years
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 3 treatment (Whole body, or, face/hand/foot) - Recommencement of treatment
after a break in biological medicine of more than 5 years
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Balance of supply - Initial 1, 2 or 3 treatment (Whole body, or, face/hand/foot)
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 1 treatment (Face, hand, foot) - biological medicine-naive patient
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 2 treatment (Face, hand, foot) - Change of treatment, or, recommencement of
treatment after a break in biological medicine of less than 5 years
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 2 | # of repeats: 4 | DPMQ: $624.84 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||